Data from Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Melissa Johnson, Alexander I. Spira(Virginia Cancer Specialists), Navid Hafez(Smilow Cancer Hospital), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Valentina Boni, Hirva Mamdani(Wayne State University), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Mark Stroh(CytomX Therapeutics (United States)), Javier Garciá Corbacho(Breast Cancer Research Foundation), Alison L. Hannah(CytomX Therapeutics (United States)), Song Wang(CytomX Therapeutics (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Henry Castro(CytomX Therapeutics (United States)), Rachel E. Sanborn(Providence Portland Medical Center)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766